摘要
目的:探讨卵巢癌患者血清激肽释放酶10(hK10)检测的临床价值。方法:用ELISA法测定30例卵巢癌患者、26例卵巢良性肿瘤患者及32例正常妇女血清中的hK10水平并以正常对照组95%可信区间的上限值为阳性标准,分析hK10在3组之间和卵巢癌患者不同临床分期间的水平和阳性率的差异。结果:正常对照组血清hK10水平的95%可信区间的上限值为0.846ng/mL;卵巢癌患者血清hK10水平及阳性率[(1.312±1.399)ng/mL、73.3%]显著高于卵巢良性肿瘤组[(0.508±0.236)ng/mL、7.7%]和正常对照组[(0.517±0.168)ng/mL、6.3%](t>2.89,χ2>24.5,P<0.01),而卵巢良性肿瘤组和正常对照组之间无明显差异(t=0.17,χ2=0.05;P>0.05)。Ⅰ/Ⅱ期与Ⅲ/Ⅳ期卵巢癌患者血清中hK10水平相比较,差异有显著性(t=1.21,P<0.05)。hK10联合CA125诊断卵巢癌的灵敏度为86.7%,特异性为87.9%,阳性预测值为78.8%,阴性预测值为92.7%,总有效率为87.5%;诊断Ⅰ/Ⅱ期卵巢癌的灵敏度从hK10或CA125单指标的40%提高到60%。结论:血清hk10是一种新的卵巢癌肿瘤标志物,对卵巢癌的诊断和临床分期有较高的临床价值,hK10与CA125联合应用可提高其早期诊断的灵敏度。
Objective To investigate the diagnostic and prognostic significance of serum human kallikreinlO （hK10） in patients with ovarian cancer. Methods The levels of serum hK10 were determined by enzyme-linked immunoassay （ELISA） for 30 patients with ovarian cancer, 26 patients with benign gynecologic processes and 32 healthy subjects, and the hK10 value beyond the upper-limit of 95% credibility interval（95%CI） based on the health controls was used as the positive value. The levels and positive rates of hK10 was compared among the three groups or between patients with stage Ⅰ/Ⅱand Ⅲ/Ⅳ ovarian cancer. Results When a cutoff 0.846ng/ml （95th percentile of the hK10 concentration in healthy subjects） was selected as the positive hK10 value, the concentrations and positive rate of hK10 in patients with ovarian cancer was significantly higher than those in patients with benign gynecologic processes or in healthy subjects [（1.312 ± 1.399） ng/mL and 73.3% vs. （0.508 ± 0.236） ng/mL and 7.7% or （0.517 ± 0.168） ng/mL and 6.3%,P 〈 0.01）]; Compared with stage Ⅰ/Ⅱ ovarian cancer patients, the serum hKlO levels and positive rate was higher in stage Ⅲ/Ⅳ patients. The diagnostic sensitivity and specificity and positive and negative expected value and accuracy for ovarian cancer of a link application of hKlO and CA125 were 86.7% and 87.9% and 78.8% and 92.7% and 87.5%, respectively, and in patients with stage Ⅰ /Ⅱ ovarian cancer, combinational use of these two markers can lead to a 20% increase in sensitivity, compared with hK10 or CA125 alone. Conclusions The serum hK10 may be a novel tumor marker in the clinical diagnosis and stage estimation for ovarian cancer, and a link application of hK10 and CA125 can increase the early diagnosis sensitivity for ovarian cancer.
出处
《实用医学杂志》
CAS
2008年第1期45-47,共3页
The Journal of Practical Medicine
基金
深圳市科技局资助项目(编号:JH200505300500A)
深圳市宝安区科技局资助项目(编号:2005108)
